Oncology

Biodesix collaborates with MRM for development of mass-spec proteomics Biodesix, the lung cancer diagnostic developer is collaborating with MRM Proteomics to authorize its iMALDI automated assay technology for quantifying proteins using mass spectrometry. It is done with the goal of enabling precision therapies. Under the agreement, Biodesix plans to use the technology to develop its blood-based lung tests that will focus on profiling the proteins and drug targets involved in the body’s larger immune response to cancer instead of the genetic alterations that may drive the growth of tumours themselves. Avoiding flu with an antibody and Tamiflu universal vaccine ...